Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2006 Sep 6

PMID 16952979

Citations 161

Authors

Yan G Ni

Kambeez Berenji

Na Wang

Misook Oh

Nita Sachan

Asim Dey

Jun Cheng

Guangrong Lu

David J Morris

Diego H Castrillon

Robert D Gerard

Beverly A Rothermel

Joseph A Hill

Affiliations

Soon will be listed here.

Abstract

Background: Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined.

Methods And Results: Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress.

Conclusions: This study suggests that inhibition of the calcineurin/NFAT signaling cascade by Foxo and release of this repressive action by the PI3K/Akt pathway are important mechanisms whereby Foxo factors govern cell growth in the heart.

Citing Articles

FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice.

Xia J, Liu K, Lin X, Li H, Lin J, Li L Nat Commun. 2025; 16(1):2532.

PMID: 40087279 DOI: 10.1038/s41467-025-57962-9.

Regression of postprandial cardiac hypertrophy in burmese pythons is mediated by FoxO1.

Martin T, Hunt D, Langer S, Tan Y, Ebmeier C, Leinwand L Proc Natl Acad Sci U S A. 2024; 121(41):e2408719121.

PMID: 39352930 PMC: 11474088. DOI: 10.1073/pnas.2408719121.

Increased Myocardial MAO-A, Atrogin-1, and IL-1β Expression in Transgenic Mice with Pancreatic Carcinoma-Benefit of MAO-A Inhibition for Cardiac Cachexia.

Stelter K, Alabssi A, Bonaterra G, Schwarzbach H, Fendrich V, Slater E Biomedicines. 2024; 12(9).

PMID: 39335522 PMC: 11428447. DOI: 10.3390/biomedicines12092009.

The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes.

Borlak J, Ciribilli Y, Bisio A, Selvaraj S, Inga A, Oh J J Transl Med. 2024; 22(1):845.

PMID: 39285385 PMC: 11403941. DOI: 10.1186/s12967-024-05623-8.

Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy.

Shafaati T, Gopal K J Pharm Pharm Sci. 2024; 27:13193.

PMID: 39206323 PMC: 11349536. DOI: 10.3389/jpps.2024.13193.

References

Van Rooij E, Doevendans P, Crijns H, Heeneman S, Lips D, Van Bilsen M . MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004; 94(3):e18-26. DOI: 10.1161/01.RES.0000118597.54416.00. View

Vega R, Bassel-Duby R, Olson E . Control of cardiac growth and function by calcineurin signaling. J Biol Chem. 2003; 278(39):36981-4. DOI: 10.1074/jbc.R300023200. View

Hosaka T, Biggs 3rd W, Tieu D, Boyer A, Varki N, Cavenee W . Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A. 2004; 101(9):2975-80. PMC: 365730. DOI: 10.1073/pnas.0400093101. View

Frey N, Katus H, Olson E, Hill J . Hypertrophy of the heart: a new therapeutic target?. Circulation. 2004; 109(13):1580-9. DOI: 10.1161/01.CIR.0000120390.68287.BB. View

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A . Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117(3):399-412. PMC: 3619734. DOI: 10.1016/s0092-8674(04)00400-3. View

Taigen T, de Windt L, Lim H, Molkentin J . Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2000; 97(3):1196-201. PMC: 15566. DOI: 10.1073/pnas.97.3.1196. View

Hill J, Karimi M, Kutschke W, Davisson R, Zimmerman K, Wang Z . Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000; 101(24):2863-9. DOI: 10.1161/01.cir.101.24.2863. View

Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T . Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2000; 279(4):H1635-44. DOI: 10.1152/ajpheart.2000.279.4.H1635. View

Yang J, Rothermel B, Vega R, Frey N, McKinsey T, Olson E . Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res. 2000; 87(12):E61-8. DOI: 10.1161/01.res.87.12.e61. View

10.

Rothermel B, McKinsey T, Vega R, Nicol R, Mammen P, Yang J . Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001; 98(6):3328-33. PMC: 30653. DOI: 10.1073/pnas.041614798. View

11.

Bodine S, Latres E, Baumhueter S, Lai V, Nunez L, Clarke B . Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-8. DOI: 10.1126/science.1065874. View

12.

Gomes M, Lecker S, Jagoe R, Navon A, GOLDBERG A . Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001; 98(25):14440-5. PMC: 64700. DOI: 10.1073/pnas.251541198. View

13.

Wang Y, De Keulenaer G, Weinberg E, Muangman S, Gualberto A, Landschulz K . Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2002; 283(2):H533-9. DOI: 10.1152/ajpheart.00002.2002. View

14.

Rothermel B, Vega R, Williams R . The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc Med. 2003; 13(1):15-21. DOI: 10.1016/s1050-1738(02)00188-3. View

15.

Tran H, Brunet A, Griffith E, Greenberg M . The many forks in FOXO's road. Sci STKE. 2003; 2003(172):RE5. DOI: 10.1126/stke.2003.172.re5. View

16.

Dugourd C, Gervais M, Corvol P, Monnot C . Akt is a major downstream target of PI3-kinase involved in angiotensin II-induced proliferation. Hypertension. 2003; 41(4):882-90. DOI: 10.1161/01.HYP.0000060821.62417.35. View

17.

Castrillon D, Miao L, Kollipara R, Horner J, DePinho R . Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science. 2003; 301(5630):215-8. DOI: 10.1126/science.1086336. View

18.

Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A . Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A. 2003; 100(20):11285-90. PMC: 208749. DOI: 10.1073/pnas.1934283100. View

19.

Stitt T, Drujan D, Clarke B, Panaro F, Timofeyva Y, Kline W . The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004; 14(3):395-403. DOI: 10.1016/s1097-2765(04)00211-4. View

20.

Accili D, Arden K . FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004; 117(4):421-6. DOI: 10.1016/s0092-8674(04)00452-0. View